{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Alector, Inc."},"Symbol":{"label":"Symbol","value":"ALEC"},"Address":{"label":"Address","value":"131 OYSTER POINT BOULEVARD SUITE 600, SOUTH SAN FRANCISCO, California, 94080, United States"},"Phone":{"label":"Phone","value":"+1 415 231-5660"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline product inlcude AL001, AL002, AL003, and AL101."},"CompanyUrl":{"label":"Company Url","value":"https://www.alector.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Arnon Rosenthal","title":"Chief Executive Officer &amp; Director"},{"name":"Charles Wolfus","title":"VP-Technology &amp; Digital Health"},{"name":"Saraswati Kenkare-Mitra","title":"President, Head-Research &amp; Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}